Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tucson, Arizona 85724


This 3 arm study will determine the dose of R1507 which will achieve a mean drug exposure in children and adolescents with advanced solid tumors equivalent to the exposure achieved in adults at the recommended dose of 9mg/kg/week. It will also determine the maximum tolerated dose (if appropriate) and the pharmacokinetic profile of R1507. Groups of patients will be sequentially enrolled in one of up to 3 dose levels (3,9mg/kg or a PK-derived dose, not to exceed 16 mg/kg) of R1507 administered weekly by intravenous infusion.An expanded cohort of patients will be enrolled at the optimal dose/MTD. The anticipated time on study treatment is until disease progression or dose limiting toxicity, and the target sample size is <100 individuals.


Inclusion Criteria: - pediatric patients aged 2-17 years of age; - histologically confirmed solid tumors; - cancer which has relapsed after, or failed to respond to, curative therapy, or no other potentially curative treatment options available. Exclusion Criteria: - treatment with corticosteroids within past 2 weeks; - current or past use of anti-IGF-1R antibodies; - current treatment with immunosuppressive agents; - patients with diabetes mellitus; - known HIV or hepatitis B or C; - hypersensitivity to any of the components of R1507 or to monoclonal antibodies.



Primary Contact:

Study Director
Clinical Trials
Hoffmann-La Roche

Backup Contact:


Location Contact:

Tucson, Arizona 85724
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.